NBIX
NASDAQNeurocrine Biosciences Inc.
Price$161.56+31.88 (+24.58%)
2026-03-192026-06-23
News · 26 weeks103-61%
2025-12-282026-06-21
Mix6490d
- Insider31(48%)
- Other19(30%)
- SEC Filings8(13%)
- Earnings3(5%)
- Analyst2(3%)
- Leadership1(2%)
Latest news
25 items- PRSoleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Following Randomized Withdrawal PeriodParticipants who resumed VYKAT XR following a 16-week randomized withdrawal period demonstrated improvements in hyperphagia and behavioral symptoms as early as Week 13, with benefits continuing through 2 yearsVYKAT XR demonstrated statistically significant and sustained improvements in hyperphagia and Prader-Willi syndrome-related behaviors for up to 3 years compared to real-world data from the PATH for PWS Natural History StudySAN DIEGO, June 15, 2026 /PRNewswire/ -- Soleno Therapeutics, a Neurocrine Biosciences (NASDAQ:NBIX) company, today announced late-breaking data at ENDO 2026 showing that resuming treatment with VYKAT® XR (diazoxide choline) extended-release tablets for two years afte
- PRNeurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY® (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11β‑Hydroxylase Deficiency at ENDO 2026Androstenedione and other adrenal hormone levels in 11β‑hydroxylase-deficient patients improved substantially after initiation of CRENESSITY, with >90% median reductions in 11-deoxycortisol and 11-deoxycorticosteroneNearly all patients (14/15) reduced their total glucocorticoid dose with CRENESSITY, and 2 of 5 patients on antihypertensive medications reduced or discontinued these drugsFindings provide initial clinical insights in patients with classic congenital adrenal hyperplasia due to 11β-hydroxylase deficiency, a rare subtype not previously studied in clinical trials of CRENESSITYSAN DIEGO, June 15, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced clinical
- PRNeurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improved Growth Measures in Pediatric Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2026Two-year data showed that pediatric patients with accelerated bone age at baseline experienced slowed bone age progression and improved predicted adult height with CRENESSITYCross-sectional caregiver survey data showed universal satisfaction with CRENESSITY, willingness to recommend treatment and increased optimism about their child's future quality of life following treatment initiationSAN DIEGO, June 15, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced new two-year data from the Phase 3 CAHtalyst® Pediatric study showing positive growth outcomes in children and adolescents with classic congenital adrenal hyperplasia treated with CRENESSITY® (crinecerfont). Pa
- PRNeurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2026Two-year CRENESSITY data in adults showed improvements in cardiometabolic outcomes of insulin resistance, body composition and body weight alongside sustained reductions in glucocorticoid doseAmong participants who were overweight or obese at baseline, 37% achieved >5% reduction in body weight at 2 years, and 43% of those with insulin resistance at baseline were no longer insulin resistant at 2 yearsFavorable trends in bone health outcomes were observed with CRENESSITY treatment, including improvements in bone mineral density with up to 2 years of treatmentPatient‑reported survey data from adults in the open-label extension suggested improvements in quality of life outcomes and treatment sat
- INSIDERDirector Sherwin Stephen A exercised 25,000 shares at a strike of $64.10 and sold $4,132,969 worth of shares (25,000 units at $165.32) as part of a pre-agreed trading plan (SEC Form 4)4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)
- INSIDERChief Scientific Officer Onyia Jude gifted 2,441 shares, decreasing direct ownership by 9% to 23,405 units (SEC Form 4)4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)
- INSIDERDirector Norwalk Leslie V sold $210,072 worth of shares (1,250 units at $168.06) as part of a pre-agreed trading plan, decreasing direct ownership by 31% to 2,838 units (SEC Form 4)4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)
- PRNeurocrine Biosciences Presents New Clinically Meaningful Response Data on Treatment of Tardive Dyskinesia, Reinforcing the Efficacy of INGREZZA® (valbenazine) Capsules Across a Broad Range of PatientsNew 48-week KINECT® 4 post-hoc analysis shows 94% of participants treated with INGREZZA achieved either symptomatic remission or a clinically meaningful response (≥30% reduction from baseline in Abnormal Involuntary Movement Scale total score); INGREZZA is the only vesicular monoamine transporter 2 (VMAT2) inhibitor to demonstrate clinical remission in clinical trialsA separate claims analysis indicates high prevalence of hepatic risk factors among patients with tardive dyskinesia; INGREZZA is the only VMAT2 inhibitor with approved dosing in hepatic impairmentTogether, these data add to a growing body of evidence supporting the potential of INGREZZA to provide clinically meaningful therapeut
- PRNeurocrine Biosciences Presents New Data Highlighting Functional and Socio-emotional Improvements with INGREZZA® (valbenazine) Capsules in Individuals with Tardive Dyskinesia and Intellectual and Developmental DisabilitiesNearly all individuals with intellectual and developmental disabilities experienced improvement in tardive dyskinesia severity after starting INGREZZA, and of those, 89% experienced improvement within 4 weeks Clinician-reported data showed improvements in key aspects of daily life following INGREZZA treatment in nearly all patients with tardive dyskinesia and intellectual and developmental disabilities who had impaired functionSAN DIEGO, June 8, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new clinician-reported data in patients with intellectual and developmental disabilities demonstrating meaningful and rapid improvements in tardive dyskinesia severity,
- INSIDERChief Human Resources Officer Cooke Julie exercised 24,965 shares at a strike of $81.49 and sold $5,770,235 worth of shares (36,937 units at $156.22) as part of a pre-agreed trading plan, decreasing direct ownership by 35% to 22,374 units (SEC Form 4)4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)
- INSIDERChief Medical Officer Keswani Sanjay Chandru converted options into 3,212 shares and covered exercise/tax liability with 1,733 shares (SEC Form 4) to satisfy tax liability4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)
- PRNeurocrine Biosciences to Present New Two‑Year CRENESSITY® (crinecerfont) Data on Key Clinical and Patient‑Reported Outcome Measures at ENDO 2026Analyses span adult and pediatric populations with classic congenital adrenal hyperplasia (CAH) and reflect longer-term clinical outcomes relevant to disease management across lifespan and care continuumNew data demonstrate the effect of CRENESSITY on long-term androgen control and glucocorticoid dose reduction and associated clinical outcomesData from cross-sectional surveys highlight patient- and caregiver-reported quality of life improvementsCase series highlights use of CRENESSITY in patients with classic CAH due to 11β‑hydroxylase deficiencyAdditional ENDO 2026 presentations include VYKAT™ XR (diazoxide choline) extended-release tablets data in hyperphagia associated with Prader-Willi s
- INSIDERChief Scientific Officer Onyia Jude exercised 11,000 shares at a strike of $84.74 and sold $1,762,710 worth of shares (11,000 units at $160.25) as part of a pre-agreed trading plan (SEC Form 4)4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)
- INSIDERChief Regulatory Officer Delaet Ingrid exercised 2,261 shares at a strike of $79.02 and sold $354,321 worth of shares (2,261 units at $156.71) as part of a pre-agreed trading plan (SEC Form 4)4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)
- ANALYSTGoldman resumed coverage on Neurocrine Biosciences with a new price targetGoldman resumed coverage of Neurocrine Biosciences with a rating of Buy and set a new price target of $213.00
- INSIDERChief Scientific Officer Onyia Jude exercised 11,000 shares at a strike of $84.74 and sold $1,710,865 worth of shares (11,000 units at $155.53) as part of a pre-agreed trading plan (SEC Form 4)4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)
- INSIDERSEC Form 4 filed by Director Gorman Kevin Charles4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)
- INSIDERSEC Form 4 filed by Director Pops Richard F4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)
- INSIDERSEC Form 4 filed by Director Lyons Gary A4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)
- INSIDERSEC Form 4 filed by Director Mercier Johanna4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)
- INSIDERSEC Form 4 filed by Director Poon Christine A4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)
- INSIDERSEC Form 4 filed by Director Sharp Shalini4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)
- INSIDERSEC Form 4 filed by Director Sherwin Stephen A4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)
- INSIDERSEC Form 4 filed by Director Morrow George J4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)
- INSIDERSEC Form 4 filed by Director Rastetter William H4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)
NBIX FAQ
7 questionsWhat does Neurocrine Biosciences Inc. do?
Neurocrine Biosciences, Inc., a biopharmaceutical company, discovers, develops, and markets pharmaceutical products for the treatment of neurological, endocrine, and psychiatric-based diseases and disorders in the United States. The company offers INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia; ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for the treatment of endometriosis pain; and ORIAHNN, a...Where does NBIX stock trade?
Neurocrine Biosciences Inc. (NBIX) is listed on NASDAQ.What sector and industry is NBIX in?
Neurocrine Biosciences Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Neurocrine Biosciences Inc. go public?
Neurocrine Biosciences Inc. (NBIX) completed its IPO in 1996.What are analysts saying about NBIX?
Neurocrine Biosciences Inc. has had 8 recent analyst actions on file. The most recent action was from Goldman: Buy on 2026-06-02.What companies are similar to NBIX?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare NBIX side-by-side with any of them on Quantisnow.How can I track NBIX on Quantisnow?
Quantisnow aggregates Neurocrine Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NBIX to receive live email and push alerts on every new disclosure.